Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916149 | 0.87 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3CYP2D6KDM4E | |
| SCHEMBL1099372 | 0.76 | ACHE (0.36) | ALDH1A1HSD17B10 | |
| SCHEMBL4737840 | 0.75 | ALDH1A1 (0.39) | SLC6A4CYP2D6KDM4EALDH1A1 | |
| SCHEMBL11916151 | 0.74 | KDM4E (0.31) | SLC6A2SLC6A4SLC6A3CYP2D6KDM4E | |
| SCHEMBL19105004 | 0.73 | ELANE (0.37) | KDM4EALDH1A1 | |
| Methyl Alcohol SCHEMBL28274629 | 0.72 | MEN1 (0.34) | ALDH1A1HSD17B10 | |
| SCHEMBL27051007 | 0.72 | — | — | |
| SCHEMBL7007318 | 0.72 | ALDH1A1 (0.46) | KDM4EALDH1A1KAT6A | |
| SCHEMBL10259660 | 0.71 | CA1 (0.31) | — | |
| SCHEMBL8570914 | 0.71 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024497-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20180222916-A1 | FUNCTIONALIZED NANOLUC INHIBITORS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20170014520-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION | 2017-01-19 | — | — | US | disclosed |
| US-20160356786-A1 | Novel Isobaric Tandem Mass Tags for Quantitative Proteomics and Peptidomics | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-12-08 | — | — | US | disclosed |
| US-9469850-B2 | Oligosaccharides comprising an aminooxy group and conjugates thereof | GENZYME CORPORATION (US) | 2016-10-18 | — | — | US | disclosed |
| US-9388132-B2 | Isobaric tandem mass tags for quantitative proteomics and peptidomics | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-20150050262-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION (US) | 2015-02-19 | — | — | US | disclosed |
| US-8759501-B2 | Oligosaccharides comprising an aminooxy group and conjugates thereof | GENZYME CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130078728-A1 | Novel Isobaric Tandem Mass Tags for Quantitative Proteomics and Peptidomics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-03-28 | — | — | US | disclosed |
| US-20100047225-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024497-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | RNGTT, RNMT, DNPEP | SLC6A2 1779/4885SLC6A4 2599/4885SLC6A3 2475/4885 |
| US-20130078728-A1 | Novel Isobaric Tandem Mass Tags for Quantitative Proteomics and Peptidomics | SRMS, TMT1A, PTMS | SLC6A2 2799/4885SLC6A4 2502/4885SLC6A3 2497/4885 |
| US-20150050262-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | SLC6A2 677/4885SLC6A4 882/4885SLC6A3 602/4885 |
| US-20170014520-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | SLC6A2 677/4885SLC6A4 882/4885SLC6A3 602/4885 |
| US-20100047225-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | SLC6A2 677/4885SLC6A4 882/4885SLC6A3 602/4885 |
| US-20180222916-A1 | FUNCTIONALIZED NANOLUC INHIBITORS | RNGTT, LUC7L2, GUSB | SLC6A2 4050/4885SLC6A4 4404/4885SLC6A3 4147/4885 |
| US-20160356786-A1 | Novel Isobaric Tandem Mass Tags for Quantitative Proteomics and Peptidomics | SRMS, TMT1A, PTMS | SLC6A2 2799/4885SLC6A4 2502/4885SLC6A3 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.